Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer

2019908 citationsJournal Articlebronze Open Access

Authors

Karim Fizazi · Institut Gustave Roussy

Neal D. Shore · Carolina Urologic Research Center

Teuvo L.J. Tammela · Tampere University

Albertas Ulys · National Cancer Institute

Egils Vjaters · Pauls Stradiņš Clinical University Hospital

S. Polyakov · N.N. Alexandrov National Cancer Centre

Mindaugas Jievaltas

Abstract

Among men with nonmetastatic, castration-resistant prostate cancer, metastasis-free survival was significantly longer with darolutamide than with placebo. The incidence of adverse events was similar for darolutamide and placebo. (Funded by Bayer HealthCare and Orion Pharma; ARAMIS ClinicalTrials.gov number, NCT02200614.).

Topics & Keywords

Prostate Cancer Treatment and Research Hormonal and reproductive studies Prostate Cancer Diagnosis and Treatment

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 380, Issue 13, pp. 1235-1246

DOI: 10.1056/nejmoa1815671

Field-Weighted Citation Impact: 95.42